Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Eli Lilly & Co. (LLY) & Other Names To Know: A Full Breakdown

Page 1 of 2

Investing in biotech companies can be intimidating, especially for investors without a science background. But there’s hope. Understanding the naming system can make things easier to piece together, giving you confidence to invest in the sector.

Pfizer Inc. (NYSE:PFE)Here’s a breakdown of some of the suffixes that biotech companies use to name their generic drugs:

-afil: Erectile dysfunction drugs that inhibit phosphodiesterase 5 usually end in -afil. Pfizer Inc. (NYSE:PFE)‘s Viagra (sildenafil), and Eli Lilly & Co. (NYSE:LLY)‘s Cialis (tadalafil) are members of the group.

-alol: Alpha and beta blockers, which includes a multitude of drugs, usually end in -alol.

-caserin: Drugs that stimulate the serotonin receptor end in caserin like Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘s  Belviq (lorcaserin). The drug is approved to treat obesity, but drugs that activate the serotonin receptor can do other things. Wyeth was developing one, vabicaserin, as an antipsychotic, for instance.

-mab: Drugs that end in -mab are usually monoclonal antibodies. Monoclonal means they bind to a protein in one specific site. Monoclonal antibodies usually inhibit the protein they’re designed to bind to. AbbVie Inc (NYSE:ABBV)‘s Humira (adalimumab), for instance, binds to tumor necrosis factor-alpha, which prevents it from activating a cascade that stimulates the immune system.

-sartan: Blood pressure drugs that block the activation of angiotensin II AT1 receptors usually end in -sartan. Merck & Co., Inc. (NYSE:MRK)‘s Cozaar (losartan) and Novartis AG (ADR) (NYSE:NVS)‘ Diovan (valsartan) are both in this class of drug.

-statin: This is an obvious one. Statins, which lower cholesterol by inhibiting HMG-CoA reductase, usually end in -statin. Interestingly, the companies also used a similar naming situation (ending the drugs in -or) for many of the brand names as well: Pfizer Inc. (NYSE:PFE)’s Lipitor (atorvastatin), Merck & Co., Inc. (NYSE:MRK)’s Zocor (simvastatin), and AstraZeneca plc (ADR) (NYSE:AZN)‘s Crestor (rosuvastatin). As far as I know, the companies weren’t required to follow a similar naming for trade names, but it probably just made sense after the first couple did it.

-vir: Most antiviral drugs end in -vir, although not every drug used to treat viral infections uses the scheme. Gilead Sciences, Inc. (NASDAQ:GILD) had two HIV drugs turned down by the Food and Drug Administration this week: elvitegravir and cobicistat. The latter doesn’t end in -vir, likely because cobicistat is considered a booster; its job in the drug cocktail is to inhibit human proteins responsible for breaking down the other drugs.

What’s in a name?
Biotech companies usually give drugs at least three different names during their development. Drugs often start with a code name. Pfizer Inc. (NYSE:PFE), for instance, names its early stage drugs PF- followed by a series of numbers. Next, biotech companies assign generic name using the system outlined by the U.S. Adopted Names Council. Finally, drugs are given a brand name that’s regulated by the FDA.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!